 | • レポートコード：MRC2301H037 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、252ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の市場調査によると、2021年の1,053.28百万ドルであった世界のヒトマイクロバイオーム市場規模は、2022年には1,291.04百万ドルへ達し、2027年までに年平均23.43%成長して3,724.81百万ドルへ拡大すると予想されています。本調査資料では、ヒトマイクロバイオームの世界市場を調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（急性下痢症、自己免疫疾患、がん、糖尿病、その他）分析、技術別（16s rRNAシーケンシング、細胞培養技術、計算道具、ハイスループット技術、その他）分析、製品別（診断装置、薬品、食品、プレバイオティクス・プロバイオティクス）分析、治療領域別（胃腸障害、代謝障害、皮膚疾患、女性の健康）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、当書では4D pharma PLC、AOBiome, LLC、Astarte Medical Partners, Inc、Axial Therapeutics, Inc.、DuPont de Nemours, Inc.、Enterome Bioscience、Evelo Biosciences, Inc.、Exeliom Biosciences SAS、Ferring B.V.、Finch Therapeutics Group, Inc.、Intralytix, Inc.、Locus Biosciences, Inc.、Merck and Co. Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界のヒトマイクロバイオーム市場規模：疾患別 - 急性下痢症における市場規模 - 自己免疫疾患における市場規模 - がんにおける市場規模 - 糖尿病における市場規模 - その他疾患における市場規模 ・世界のヒトマイクロバイオーム市場規模：技術別 - 16s rRNAシーケンシングにおける市場規模 - 細胞培養技術における市場規模 - 計算道具における市場規模 - ハイスループット技術における市場規模 - その他技術における市場規模 ・世界のヒトマイクロバイオーム市場規模：製品別 - 診断装置の市場規模 - 薬品の市場規模 - 食品の市場規模 - プレバイオティクス・プロバイオティクスの市場規模 ・世界のヒトマイクロバイオーム市場規模：治療領域別 - 胃腸障害における市場規模 - 代謝障害における市場規模 - 皮膚疾患における市場規模 - 女性の健康における市場規模 ・世界のヒトマイクロバイオーム市場規模：地域別 - 南北アメリカのヒトマイクロバイオーム市場規模 アメリカのヒトマイクロバイオーム市場規模 カナダのヒトマイクロバイオーム市場規模 ブラジルのヒトマイクロバイオーム市場規模 ... - アジア太平洋のヒトマイクロバイオーム市場規模 日本のヒトマイクロバイオーム市場規模 中国のヒトマイクロバイオーム市場規模 インドのヒトマイクロバイオーム市場規模 韓国のヒトマイクロバイオーム市場規模 台湾のヒトマイクロバイオーム市場規模 ... - ヨーロッパ/中東/アフリカのヒトマイクロバイオーム市場規模 イギリスのヒトマイクロバイオーム市場規模 ドイツのヒトマイクロバイオーム市場規模 フランスのヒトマイクロバイオーム市場規模 ロシアのヒトマイクロバイオーム市場規模 ... - その他地域のヒトマイクロバイオーム市場規模 ・競争状況 ・企業情報 |
The Global Human Microbiome Market size was estimated at USD 1,053.28 million in 2021 and expected to reach USD 1,291.04 million in 2022, and is projected to grow at a CAGR 23.43% to reach USD 3,724.81 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Human Microbiome to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Disease, the market was studied across Acute Diarrhea, Autoimmune Disorders, Cancer, Diabetes, Mental Disorders, and Obesity.
Based on Technology, the market was studied across 16s rRNA Sequencing, Cell Culture Technology, Computational Tools, High-Throughput Technology, Metagenomic Sequencing, and Omics Technology.
Based on Product, the market was studied across Diagnostic Devices, Drugs, Foods, and Prebiotic & Probiotics.
Based on Therapeutic Area, the market was studied across Gastrointestinal Disorders, Metabolic Disorders, Skin Disorders, and Women’s Health.
Based on Application, the market was studied across Diagnostics and Therapeutics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Connecticut, Florida, Illinois, Maryland, Minnesota, New Jersey, New York, Ohio, Pennsylvania, Texas, and Washington. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Human Microbiome market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Human Microbiome Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Human Microbiome Market, including 4D pharma PLC, AOBiome, LLC, Astarte Medical Partners, Inc, Axial Therapeutics, Inc., DuPont de Nemours, Inc., Enterome Bioscience, Evelo Biosciences, Inc., Exeliom Biosciences SAS, Ferring B.V., Finch Therapeutics Group, Inc., Intralytix, Inc., Locus Biosciences, Inc., Merck and Co. Inc., Metabiomics Corporation, Osel Inc., Second Genome, Inc., Seres Therapeutics, Inc., Synlogic, Inc., Synthetic Biologics, Inc., Vedanta Biosciences, Inc., and Yakult Honsha Co., Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Human Microbiome Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Human Microbiome Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Human Microbiome Market?
4. What is the competitive strategic window for opportunities in the Global Human Microbiome Market?
5. What are the technology trends and regulatory frameworks in the Global Human Microbiome Market?
6. What is the market share of the leading vendors in the Global Human Microbiome Market?
7. What modes and strategic moves are considered suitable for entering the Global Human Microbiome Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased Focus on Development of Human Microbiome Therapy
5.1.1.2. Human Microbiome for Drug Discovery, Early Disease Detection, and Diagnosis
5.1.1.3. Increasing Demand for Microbiome in Probiotics and Infant Nutrition
5.1.2. Restraints
5.1.2.1. Limited Expertise and Safety Issue related to Microbiome Therapeutics
5.1.3. Opportunities
5.1.3.1. Increasing Collaborations and Research Investments to Create Growth Opportunities
5.1.3.2. Development of Novel Human Microbiome Therapeutic Products
5.1.4. Challenges
5.1.4.1. Limitations in Understanding Number of Bacterial Species and Uncertainty of Human Microbiome-Based Drugs
5.2. Cumulative Impact of COVID-19
6. Human Microbiome Market, by Disease
6.1. Introduction
6.2. Acute Diarrhea
6.3. Autoimmune Disorders
6.4. Cancer
6.5. Diabetes
6.6. Mental Disorders
6.7. Obesity
7. Human Microbiome Market, by Technology
7.1. Introduction
7.2. 16s rRNA Sequencing
7.3. Cell Culture Technology
7.4. Computational Tools
7.5. High-Throughput Technology
7.6. Metagenomic Sequencing
7.7. Omics Technology
8. Human Microbiome Market, by Product
8.1. Introduction
8.2. Diagnostic Devices
8.3. Drugs
8.4. Foods
8.5. Prebiotic & Probiotics
9. Human Microbiome Market, by Therapeutic Area
9.1. Introduction
9.2. Gastrointestinal Disorders
9.3. Metabolic Disorders
9.4. Skin Disorders
9.5. Women’s Health
10. Human Microbiome Market, by Application
10.1. Introduction
10.2. Diagnostics
10.3. Therapeutics
11. Americas Human Microbiome Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Human Microbiome Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Human Microbiome Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. 4D pharma PLC
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. AOBiome, LLC
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Astarte Medical Partners, Inc
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. Axial Therapeutics, Inc.
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. DuPont de Nemours, Inc.
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Enterome Bioscience
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Evelo Biosciences, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. Exeliom Biosciences SAS
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. Ferring B.V.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Finch Therapeutics Group, Inc.
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Intralytix, Inc.
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. Locus Biosciences, Inc.
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. Merck and Co. Inc.
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. Metabiomics Corporation
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Osel Inc.
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Second Genome, Inc.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Seres Therapeutics, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Synlogic, Inc.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Synthetic Biologics, Inc.
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Vedanta Biosciences, Inc.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. Yakult Honsha Co., Ltd.
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing